期刊文献+
共找到2篇文章
< 1 >
每页显示 20 50 100
大麻基因组DNA提取及AFLP体系的建立 被引量:4
1
作者 陈璇 胡尊红 +4 位作者 郭鸿彦 张庆滢 许艳萍 郭孟璧 杨明 《分子植物育种》 CAS CSCD 2010年第3期619-625,共7页
本研究以大麻嫩叶为材料,以改进的SDS法,提取了高质量的大麻基因组DNA,经过酶切、连接、预扩增、选择性扩增、银染等试验条件的优化,建立了AFLP反应体系。研究结果表明:在常规的SDS提取液里加入8μL/mLβ-巯基乙醇(V/V)和3%PVP(M/V)能... 本研究以大麻嫩叶为材料,以改进的SDS法,提取了高质量的大麻基因组DNA,经过酶切、连接、预扩增、选择性扩增、银染等试验条件的优化,建立了AFLP反应体系。研究结果表明:在常规的SDS提取液里加入8μL/mLβ-巯基乙醇(V/V)和3%PVP(M/V)能够提取到高质量的适用于AFLP的基因组DNA;选取150ng大麻基因组DNA来进行酶切,EcoRⅠ和MseⅠ各0.5U,在37℃酶切4h,即可完全酶切。最优的选择性扩增体系为20μL反应体系中含有1.0U Taq DNA polymerase、1.0μL25mmol/L Mg2+、0.4μL10mmol/LdNTPs、50ng/μL引物各1.0μL、4.0μL稀释50倍的预扩增产物及2μL10×PCR Buffer;使用该方法,获得了清晰、稳定的图谱并筛选到了18对多态性较好的AFLP引物组合。 展开更多
关键词 抗大麻 DNA提取 优化 AFLP
下载PDF
The endocannabinoid system:A new pharmacological target for obesity treatment?
2
作者 胡佳 朱超 黄矛 《Neuroscience Bulletin》 SCIE CAS CSCD 2009年第3期153-160,共8页
Being a great threaten for human health, obesity has become a pandemic chronic disease. There have been several therapeutic treatments for this social health issue, including diet and exercise therapy, medication and ... Being a great threaten for human health, obesity has become a pandemic chronic disease. There have been several therapeutic treatments for this social health issue, including diet and exercise therapy, medication and surgery, among which the diet is still the most common way. However, none of these therapeutic measures available is ideal, making it necessary to find an effective medical treatment. The endocannabinoid system, which is well known for its contributions in certain mental processes such as relaxation, amelioration of pain and anxiety, and sedation initiation, has been recently reported to play an essential role in regulating appetite and metabolism to maintain energy balance, leading to the belief that endocannabinoid system is closely related to obesity. This new discovery deepens our understanding of obesity, and provides us with a new direction for clinical obesity treatment. Rimonabant is an antagonist for CB1, and has entered the market in some countries. However, although effective as an anti-obesity drug, rimonabant also causes obviously adverse side-effects, thus is being doubted and denied for medical usage. 展开更多
关键词 OBESITY weight loss ENDOCANNABINOIDS cannabinoid receptor cannabinoid CB1 receptor antagonist anti-obesity agents RIMONABANT
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部